ArticleJournal of molecular histology2026
Cherry plum powder alleviates excessive proliferation and inflammation of keratinocytes in psoriasis by reducing N6 methyladenosine-modified S100A4.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cherry plum powder (CPP) is a pure natural plant extract with antioxidant and anti-inflammatory effects, and its role in psoriasis has not yet been elucidated. In this study, Balb/c mice were treated by imiquimod (IMQ) for a consecutive 7 days to establish psoriasis models, and then administrated with CPP by gavage for 2 weeks. CPP treatment obviously alleviated IMQ-induced psoriasis-like dermatitis, epidermal thickening and inflammatory cytokines secretion in mice. Through in vitro keratinocytes models, CPP was also found to suppress tumor necrosis factor tumor necrosis factor-alpha (TNF-α)-induced excessive proliferation and inflammatory cytokines production in HaCaT cells. Besides, CPP significantly reduced the expression of soluble protein 100 protein A4 (S100A4) and the phosphorylation of phosphatidylinositol 3-kinase (PI3K) and serine/threonine kinase (AKT) in psoriasis models in vivo and in vitro. In mechanism, methyltransferase-like protein 14 (METTL14)-mediated N6 methyladenosine (m6A) methylation stabilized and upregulated S100A4 mRNA, and then activated the downstream PI3K/AKT signaling, which was reversed by CPP treatment. Overexpression of METTL14 or S100A4 counteracted the therapeutic effects of CPP on TNF-α-induced HaCaT cells, which were then restored by a PI3K inhibitor. To conclude, CPP alleviates excessive proliferation and inflammation of keratinocyte to improve psoriasis through suppressing METTL14-mediated m6A modification of S100A4 mRNA and inactivating the downstream PI3K/AKT signaling pathway.
Indexed as
Identifiers
42050231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.